Focus: Biohaven is a publicly traded biotechnology company headquartered in New Haven, CT, focused on small molecules for neurology indications. The company maintains a diversified pipeline spanning neurodegenerative, psychiatric, and orphan neurology disorders.
Profile data last refreshed Yesterday · AI intelligence enriched 2mo ago
No open roles listed right now. Follow Biohaven to get notified when they start hiring — the background below is worth knowing for when they do.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Biohaven
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Biohaven's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Biohaven stock jumps on positive drug trial results - Investing.com
Biohaven stock jumps on positive drug trial results Investing.com
Biohaven Pharmaceutical Holding Co receives Investment Bank Analyst Rating Update By Investing.com - Investing.com India
Biohaven Pharmaceutical Holding Co receives Investment Bank Analyst Rating Update By Investing.com Investing.com India
H.C. Wainwright reiterates Biohaven stock rating ahead of trial - Investing.com
H.C. Wainwright reiterates Biohaven stock rating ahead of trial Investing.com
BHVN Stock Price Prediction 2025-2026 | Biohaven Pharmaceutical Holding Co Ltd Forecast | 24/7 Wall St. - 24/7 Wall St.
BHVN Stock Price Prediction 2025-2026 | Biohaven Pharmaceutical Holding Co Ltd Forecast | 24/7 Wall St. 24/7 Wall St.
Biohaven Pharma (BHVN) files mixed shelf - StreetInsider
Biohaven Pharma (BHVN) files mixed shelf StreetInsider
Canaccord Starts Biohaven Pharma (BHVN) at Buy - StreetInsider
Canaccord Starts Biohaven Pharma (BHVN) at Buy StreetInsider
Showing 6 of 10 news items
No open positions listed yet. Check their careers page directly.
Recent peer-reviewed publications with author affiliations at this company
Multiple System Atrophy Combined Outcome Assessment (MuSyCA): process, format, and validation plan.
Incorporating Patient Perspectives into a Composite Score for Measuring Disease Progression in Spinocerebellar Ataxia (SCA).
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo